Insights

Innovative Focus SHINKEI Therapeutics specializes in repurposing existing pharmaceutical products for CNS disorders using the 505(b)2 regulatory strategy, providing opportunities to introduce improved drug formulations with faster approval timelines and potentially lower development costs.

Collaborative Expansion The company's partnership with the FDA for its IND filing on MR-201 indicates a strong trajectory toward bringing novel CNS treatments to market, opening doors for health systems and clinics focusing on CNS conditions to adopt new therapeutic options.

Market Niche With a focus on CNS disorders like Pseudobulbar Affect, SHINKEI operates in a specialized segment with less direct competition but high demand for innovative treatments, creating opportunities to establish relationships with neurologists and mental health specialists.

Growing Pipeline SHINKEI's diversified pipeline emphasizing drug administration improvements and side-effect reduction aligns with emerging market trends favoring patient-centric therapies, presenting opportunities to collaborate with healthcare providers seeking advanced treatment solutions.

Technology Leverage Utilizing modern cloud and web technologies, SHINKEI maintains an agile and cost-efficient operations model, allowing for flexibility in trial management and communications—beneficial for partners interested in agile, innovative collaborations.

Similar companies to SHINKEI Therapeutics

SHINKEI Therapeutics Tech Stack

SHINKEI Therapeutics uses 8 technology products and services including Cloudflare CDN, Cloudflare, Google Fonts API, and more. Explore SHINKEI Therapeutics's tech stack below.

Cloudflare CDN
Content Delivery Network
Cloudflare
Content Management System
Google Fonts API
Font Scripts
OWL Carousel
Javascript Libraries
jQuery
Javascript Libraries
PHP
Programming Languages
Hostinger
Web Hosting
LiteSpeed
Web Servers

Media & News

SHINKEI Therapeutics partnered with U.S. Food and Drug Administration on Aug 21st '19.
SHINKEI Therapeutics, a clinical stage pharmaceutical company focused on the development of drugs for the treatment of Central Nervous System (CNS) disorders, today announced the filing of an Investigational New Drug (“IND”) application with the U.S. Food and Drug Administration (“FDA”) of MR-201, a novel dosage form for the treatment of Pseudobulbar Affect (PBA).
Aug 21, 2019 | www.globenewswire.com

SHINKEI Therapeutics's Email Address Formats

SHINKEI Therapeutics uses at least 1 format(s):

SHINKEI Therapeutics Email Formats	Example	Percentage
LastF@shinkeitherapeutics.com	DoeJ@shinkeitherapeutics.com	35%
FLast@shinkeitherapeutics.com	JDoe@shinkeitherapeutics.com	15%
LastF@shinkeitherapeutics.com	DoeJ@shinkeitherapeutics.com	35%
FLast@shinkeitherapeutics.com	JDoe@shinkeitherapeutics.com	15%

Frequently Asked Questions

What is SHINKEI Therapeutics's official website and social media links?

SHINKEI Therapeutics's official website is shinkeitherapeutics.com and has social profiles on LinkedIn.

What is SHINKEI Therapeutics's NAICS code?

SHINKEI Therapeutics's NAICS code is 3254 - Pharmaceutical and Medicine Manufacturing.

How many employees does SHINKEI Therapeutics have currently?

As of December 2025, SHINKEI Therapeutics has approximately 5 employees across 2 continents, including North AmericaAsia. Key team members include Vice President Strategic Partnerships: K. P.Vice President And General Counsel: M. G.Executive Chairman: G. S.. Explore SHINKEI Therapeutics's employee directory with LeadIQ.

What industry does SHINKEI Therapeutics belong to?

SHINKEI Therapeutics operates in the Pharmaceutical Manufacturing industry.

What technology does SHINKEI Therapeutics use?

SHINKEI Therapeutics's tech stack includes Cloudflare CDNCloudflareGoogle Fonts APIOWL CarouseljQueryPHPHostingerLiteSpeed.

What is SHINKEI Therapeutics's email format?

SHINKEI Therapeutics's email format typically follows the pattern of LastF@shinkeitherapeutics.com. Find more SHINKEI Therapeutics email formats with LeadIQ.

When was SHINKEI Therapeutics founded?

SHINKEI Therapeutics was founded in 2017.

SHINKEI Therapeutics

Q: How many employees does SHINKEI Therapeutics have currently?

SHINKEI Therapeutics has approximately 5 employees.

Q: What technology does SHINKEI Therapeutics use?

SHINKEI Therapeutics's tech stack includes OWL Carousel, jQuery, Hostinger, Cloudflare, HTTP/3.

Pharmaceutical ManufacturingNew Jersey, United States2-10 Employees

SHINKEI is a clinical stage CNS (Central Nervous System) disorders focused pharmaceutical company using the 505(b)2 regulatory strategy to repurpose existing pharmaceutical products for faster and better patient outcome. We have a diversified and robust product development pipeline focus on improving a drug’s administration such that it allows use in indications not previously possible, enhances the convenience, improves compliance, and/or ameliorates the side-effects profile for patients SHINKEI was co-founded by Suresh Borsadia and GP Singh, industry veterans, having the mix of commercial and scientific backgrounds. They are supported by a nimble and efficient team of professionals, advisors and consultants.